Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation
Authors
Keywords
Chronic mucocutaneous candidiasis, candida, signal transducer and activator of transcription 1, Janus kinase inhibitor, ruxolitinib
Journal
JOURNAL OF CLINICAL IMMUNOLOGY
Volume 38, Issue 5, Pages 589-601
Publisher
Springer Nature
Online
2018-06-22
DOI
10.1007/s10875-018-0519-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CD49a Expression Defines Tissue-Resident CD8 + T Cells Poised for Cytotoxic Function in Human Skin
- (2017) Stanley Cheuk et al. IMMUNITY
- Impaired natural killer cell functions in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations
- (2017) Giovanna Tabellini et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation
- (2017) Katja G. Weinacht et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease
- (2017) Ofer Zimmerman et al. Open Forum Infectious Diseases
- T regulatory lymphocytes in type 1 diabetes: Impaired CD25 expression and IL-2 induced STAT5 phosphorylation in pediatric patients
- (2016) Zuzana Parackova et al. AUTOIMMUNITY
- Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype
- (2016) J. Toubiana et al. BLOOD
- Ruxolitinib Induces Interleukin 17 and Ameliorates Chronic Mucocutaneous Candidiasis Caused by STAT1 Gain-of-Function Mutation
- (2016) Rotraut Mössner et al. CLINICAL INFECTIOUS DISEASES
- Severe Early-Onset Combined Immunodeficiency due to Heterozygous Gain-of-Function Mutations in STAT1
- (2016) Safa Baris et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC)
- (2015) Jie Zheng et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- Immunotherapy with G-CSF in patients with chronic mucocutaneous candidiasis
- (2015) Frank L. van de Veerdonk et al. IMMUNOLOGY LETTERS
- Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation
- (2015) Eleanor Higgins et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Monogenic mutations differentially affect the quantity and quality of T follicular helper cells in patients with human primary immunodeficiencies
- (2015) Cindy S. Ma et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)
- (2015) Mignon L. Loh et al. PEDIATRIC BLOOD & CANCER
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- A Negative Feedback Loop Mediated by STAT3 Limits Human Th17 Responses
- (2014) H. A. Purvis et al. JOURNAL OF IMMUNOLOGY
- The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders
- (2013) Yasuko Furumoto et al. BIODRUGS
- Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects
- (2013) Hagop M. Kantarjian et al. Clinical Lymphoma Myeloma & Leukemia
- Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation–polyendocrinopathy–enteropathy–X-linked–like syndrome
- (2013) Gulbu Uzel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Gain-of-function STAT1 mutations are associated with PD-L1 overexpression and a defect in B-cell survival
- (2013) Neil Romberg et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Fatal combined immunodeficiency associated with heterozygous mutation in STAT1
- (2013) Nigel Sharfe et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Human Natural Killer Cells Acting as Phagocytes Against Candida albicans and Mounting an Inflammatory Response That Modulates Neutrophil Antifungal Activity
- (2013) Jessica Voigt et al. JOURNAL OF INFECTIOUS DISEASES
- New and recurrent gain-of-functionSTAT1mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe
- (2013) Beáta Soltész et al. JOURNAL OF MEDICAL GENETICS
- Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis
- (2012) Anne Puel et al. Current Opinion in Allergy and Clinical Immunology
- Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes
- (2012) Stephanie Boisson-Dupuis et al. CURRENT OPINION IN IMMUNOLOGY
- Inborn Errors of Human JAKs and STATs
- (2012) Jean-Laurent Casanova et al. IMMUNITY
- Molecular mechanisms of mucocutaneous immunity against Candida and Staphylococcus species
- (2012) László Maródi et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Challenges Facing JAK Inhibitor Therapy for Myeloproliferative Neoplasms
- (2012) Ayalew Tefferi NEW ENGLAND JOURNAL OF MEDICINE
- Type I interferonopathies: a novel set of inborn errors of immunity
- (2011) Yanick J. Crow Annals of the New York Academy of Sciences
- Growth hormone-STAT5 regulation of growth, hepatocellular carcinoma, and liver metabolism
- (2011) Myunggi Baik et al. Annals of the New York Academy of Sciences
- Gain-of-function humanSTAT1mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis
- (2011) Luyan Liu et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
- (2011) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- The Influence of Excessive IL-6 Production In Vivo on the Development and Function of Foxp3+ Regulatory T Cells
- (2010) M. Fujimoto et al. JOURNAL OF IMMUNOLOGY
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- V 1 T lymphocytes producing IFN- and IL-17 are expanded in HIV-1-infected patients and respond to Candida albicans
- (2009) D. Fenoglio et al. BLOOD
- A phosphorylation-acetylation switch regulates STAT1 signaling
- (2009) O. H. Kramer et al. GENES & DEVELOPMENT
- IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells
- (2008) T. Korn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now